Target intelligence / Profile preview

Mothers against decapentaplegic homolog 7 (Smad7) ubiquitin–proteasome regulatory machinery (Smad7-UPS)

Target
Smad7-UPS
Molecular classification
Enzyme, Transcription factor, Other
01

Overview

The Smad7 ubiquitin–proteasome regulatory machinery is a critical biochemical system that modulates the intensity and duration of the Transforming Growth Factor-beta (TGF-beta) and Bone Morphogenetic Protein (BMP) signaling pathways (Kavsak et al., 2000). Smad7, an inhibitory Smad (I-Smad), acts as a scaffold or adaptor protein that recruits E3 ubiquitin ligases, such as SMURF1 and SMURF2, to activated TGF-beta type I receptors (TβRI) (Ebisawa et al., 2001). This recruitment facilitates the polyubiquitination and subsequent proteasomal degradation of the receptor complex, effectively terminating the signal (Kavsak et al., 2000). Conversely, the machinery also regulates Smad7 itself; Smad7 is targeted for degradation by various E3 ligases, a process that can be inhibited by post-translational modifications like acetylation by p300 (Monteleone et al., 2008). Dysregulation of this machinery is implicated in several diseases, notably inflammatory bowel disease (IBD), where Smad7 overexpression blocks anti-inflammatory TGF-beta signaling (Monteleone et al., 2015). In contrast, various fibrotic disorders are characterized by Smad7 deficiency or accelerated degradation, leading to uncontrolled TGF-beta activity and excessive tissue scarring (Source 1.4.1). Therapeutic strategies include antisense oligonucleotides like Mongersen (GED-0301) to reduce Smad7 levels in IBD and potential small molecules to stabilize Smad7 in fibrotic conditions (Monteleone et al., 2015). The machinery's role as a gatekeeper of TGF-beta signaling makes it a high-value target for precision medicine in chronic inflammatory and fibrotic diseases.

Other names
Smad7-Smurf complexSmad7-Smurf1/2 E3 ubiquitin ligase complexSmad7 degradation machineryI-Smad regulatory machinerySmad7-mediated receptor degradation complex
02

Mechanism of action

Antisense oligonucleotide-mediated knockdown of Smad7 mRNA to restore TGF-beta signaling; Inhibition of the proteasome to prevent Smad7 or receptor degradation; Modulation of Smad7 acetylation to prevent ubiquitination.

03

Biological functions

Signal transductionProtein degradationImmune responseCell proliferationApoptosisFibrosis regulation
04

Disease associations

InflammationCancerCardiovascular diseaseFibrosisInflammatory bowel disease
05

Safety considerations

Risk of excessive TGF-beta signaling leading to systemic fibrosisRisk of suppressed TGF-beta signaling leading to chronic inflammation or loss of tumor suppressionOff-target effects associated with systemic proteasome inhibitionPotential for injection site reactions or systemic immune responses to antisense therapy
06

Interacting drugs

Mongersen

4 more in the full profile.

07

Biomarkers

Smad7 protein expressionSmad7 acetylation statusPhosphorylated Smad2/3 levelsTGF-beta receptor 1 (ALK5) levels

Beyond the preview

Go deeper on Mothers against decapentaplegic homolog 7 (Smad7) ubiquitin–proteasome regulatory machinery (Smad7-UPS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mothers against decapentaplegic homolog 7 (Smad7) ubiquitin–proteasome regulatory machinery (Smad7-UPS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call